Print Page  Close Window

Press Release

Orexigen Therapeutics Announces Third Quarter 2017 Financial Results
Orexigen reports Contrave total third quarter prescription volume in the United States grew 26% year-over-year

SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2017.

Orexigen Therapeutics Recent Business Highlights:

  • Drove 26% increase in Contrave® (naltrexone HCl / bupropion HCl extended release) total prescription volume in the United States in the third quarter of 2017 relative to the third quarter of 2016
  • Received positive U.S District Court ruling regarding its patent litigation with Actavis, providing market exclusivity for Contrave into 2030
  • Launched successful fall advertising campaign which, for the first time, featured active promotion of the "Get Contrave Now" website and the innovative telemedicine platform supporting the prescribing of Contrave through online or telephone-based physician consultations, with free-home delivery
  • Finalized commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for Latin America, including Brazil and Mexico; Contrave/Mysimba™ is now partnered in 67 markets and launched in 17 countries, with 10-15 additional international launches expected by the end of the first quarter of 2018

"Our performance in the third quarter of 2017 reflects the continued success of the commercial strategy we launched late last year. The dramatic results generated by the launch of the next phase of our patient-activation campaign in September supports our thesis that we can drive significant growth in Contrave sales but at a substantially lower cost than that of a more-traditional primary care selling model," said Mike Narachi, President and Chief Executive Officer of Orexigen.  Mike continued, "Adding to our continued, strong year-over-year business performance, the recently-announced positive decision from the U.S. District Court regarding our patent litigation with Actavis has solidified our intellectual property portfolio and provides Contrave with market exclusivity into 2030. This broad window of market exclusivity, coupled with growing global Contrave/Mysimba sales, positions Orexigen for over a decade of profitable growth beginning in 2019, the year in which we have previously guided that we expect to achieve profitability."

Business and financial results for the three months ended September 30, 2017

According to data compiled by IMS Health and telemedicine partners working with Orexigen, 208,397 total prescriptions of Contrave were filled in the third quarter of 2017, as compared to 164,746 total prescriptions filled in the third quarter of 2016.

Orexigen reported third quarter 2017 revenue of $18.9 million, including $17.8 million in net sales of Contrave in the United States, and $1.1 million in combined net sales to partners outside the United States and milestone income.  In the third quarter of 2016, Orexigen recorded total revenue of $7.0 million, including $1.8 million of combined collaborative income and royalties earned on U.S. net sales of Contrave generated by our former partner in July 2016 prior to the completed acquisition of Contrave by Orexigen and $5.2 million of U.S. net sales of Contrave generated by Orexigen in August and September 2016 following the completed acquisition.   The combined total net sales of Contrave in the United States during the third quarter of 2016, as reported by Orexigen and our former partner were $9.6 million.

Total operating expenses for the third quarter of 2017 were $37.6 million compared to a credit of $37.5 million for the third quarter of 2016.  Third quarter 2016 operating expense was impacted by a non-cash settlement gain of $80.2 million resulting from the elimination of previously-recorded pre-existing deferred revenue.

For the three months ended September 30, 2017, Orexigen reported a net loss of $20.8 million, or $1.35 per share.

As of September 30, 2017, Orexigen had $70.6 million in cash, cash equivalents and marketable securities.

Conference Call Today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)

The Orexigen management team will host a teleconference and webcast to discuss the third quarter 2017 financial results and recent business highlights.  The live call may be accessed by phone by (800) 708-4539 (domestic) or (847) 619-6396 (international), participant code 45886353.  The webcast can be accessed live on the Investors section of the Orexigen web site at, and will be archived for 14 days following the call.

About Contrave and Mysimba

Contrave, marketed as Mysimba in the European Union, is a prescription-only, FDA-approved weight-loss medication believed to work on two areas of the brain—the hunger center and the reward system—to reduce hunger and help control cravings.  The exact neurochemical effects of Contrave/Mysimba leading to weight loss are not fully understood.  Contrave/Mysimba contains two medicines, bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine and naltrexone, an opioid antagonist.

Contrave, approved by the FDA in September 2014, is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia).  In the European Union, Mysimba was approved in March 2015.

Orexigen is committed to helping eligible patients learn about Contrave and recommends patients in the U.S. visit for additional information. 

For full U.S. prescribing information please visit

Important Safety Information for CONTRAVE and MYSIMBA (per U.S. prescribing information)

(naltrexone HCl and bupropion HCl) 8 mg/90 mg extended-release tablets

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults.  CONTRAVE patients should be monitored for suicidal thoughts and behaviors.  In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported.  CONTRAVE is not approved for use in children under the age of 18.

Stop taking CONTRAVE and call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempts to commit suicide; depression; anxiety; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); irritability; aggression, anger, or violence; acting on dangerous impulses; an extreme increase in activity and talking (mania); other unusual changes in behavior or mood.

Do not take CONTRAVE if you have uncontrolled high blood pressure; have or have had seizures; use other medicines that contain bupropion such as WELLBUTRIN, APLENZIN or ZYBAN; have or have had an eating disorder; are dependent on opioid pain medicines or use medicines to help stop taking opioids such as methadone or buprenorphine, or are in opiate withdrawal; drink a lot of alcohol and abruptly stop drinking; are allergic to any of the ingredients in CONTRAVE; or are pregnant or planning to become pregnant.

Before taking CONTRAVE, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not take any other medicines while you are taking CONTRAVE unless your healthcare provider says it is okay.

Tell your healthcare provider about all of your medical conditions including if you have: depression or other mental illnesses; attempted suicide; seizures; head injury; tumor or infection of brain or spine; low blood sugar or low sodium; liver or kidney problems; high blood pressure; heart attack, heart problems, or stroke; eating disorder; drinking a lot of alcohol; prescription medicine or street drug abuse; are 65 or older; diabetes; pregnant; or breastfeeding.

CONTRAVE may cause serious side effects, including:

Seizures.  There is a risk of having a seizure when you take CONTRAVE.  If you have a seizure, stop taking CONTRAVE, tell your healthcare provider right away.    

Risk of opioid overdose.  Do not take large amounts of opioids, including opioid-containing medicines, such as heroin or prescription pain pills, to try to overcome the opioid-blocking effects of naltrexone.

Sudden opioid withdrawal.  Do not use any type of opioid for at least 7 to 10 days before starting CONTRAVE.

Severe allergic reactions.  Stop taking CONTRAVE and get medical help immediately if you have any signs and symptoms of severe allergic reactions: rash, itching, hives, fever, swollen lymph glands, painful sores in your mouth or around your eyes, swelling of your lips or tongue, chest pain, or trouble breathing.

Increases in blood pressure or heart rate.

Liver damage or hepatitis.  Stop taking CONTRAVE if you have any symptoms of liver problems: stomach area pain lasting more than a few days, dark urine, yellowing of the whites of your eyes, or tiredness.

Manic episodes.

Visual problems (angle-closure glaucoma).  Signs and symptoms may include: eye pain, changes in vision, swelling or redness in or around the eye.

Increased risk of low blood sugar (hypoglycemia) in people with type 2 diabetes mellitus who also take medicines to treat their diabetes (such as insulin or sulfonylureas).

The most common side effects of CONTRAVE include nausea, constipation, headache, vomiting, dizziness, trouble sleeping, dry mouth, and diarrhea.

These are not all the possible side effects of CONTRAVE. Tell your healthcare provider about any side effect that bothers you or does not go away.


CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

  • CONTRAVE should be used with a reduced-calorie diet and increased physical activity
  • It is not known if CONTRAVE changes your risk of heart problems or stroke or of death due to heart problems or stroke
  • It is not known if CONTRAVE is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products

CONTRAVE is not approved to treat depression or other mental illnesses, or to help people quit smoking (smoking cessation).  One of the ingredients in CONTRAVE, bupropion, is the same ingredient in some other medicines used to treat depression and to help people quit smoking.

Ask your doctor or healthcare professional if CONTRAVE is right for you.  Please see Full Prescribing Information, including Medication Guide, for CONTRAVE.

You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit or call 1‑800‑FDA‑1088.

About Obesity & Weight Loss

Obesity is a serious and rising health epidemic and has been declared a disease by the American Medical Association.  It is estimated that about 110 million adults are overweight or struggling with obesity; however, only 3% are treated with a prescription weight loss medicine.  By 2030, the percentage of Americans who struggle with obesity could reach 51%.  Obesity can increase the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions.  Weight loss is complex and for many people diet and exercise alone may not be enough.  Two areas of the brain play an important role in weight loss.  The hypothalamus, your hunger center, regulates hunger and the mesolimbic reward system can cause cravings even when you are not hungry.  Other areas of the brain may be involved.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of weight loss and obesity.  Our mission is to help improve the health and lives of patients struggling to lose weight.  Orexigen's first product, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the U.S. in September 2014 and became the #1 prescription weight loss brand in the U.S. in June 2015.  In the European Union, the medicine has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged release).  Millions around the globe continue to face challenges of weight loss.  Orexigen is undertaking a range of development and commercialization activities, both on its own and with strategic partners, to bring Contrave/Mysimba to patients around the world.  As a patient-centric company, we continue to focus not only on innovating medicine for the treatment of obesity, but to also offer unique resources and healthcare delivery options to improve the patient experience.  Further information about Orexigen can be found at

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the company's current beliefs and expectations.  These forward-looking statements include statements regarding: the potential success of marketing and commercialization of Contrave/Mysimba in the United States and elsewhere; expectations regarding Orexigen's future profitability; and the potential growth of Contrave/Mysimba sales.

The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the potential that the marketing and commercialization of Contrave/Mysimba will not be successful; the company's ability to obtain and maintain partnerships and the ability of it or its partners to maintain marketing authorization globally; the company's ability to adequately inform consumers about Contrave; the company's ability to successfully commercialize Contrave with a specialty sales force in the United States; the capabilities and performance of various third parties on which it relies for a number of activities related to the manufacture, development and commercialization of Contrave/Mysimba; the estimates of the capacity of manufacturing and the company's ability to secure additional manufacturing capabilities; the company's ability to successfully complete the post-marketing requirement studies for Contrave; the therapeutic and commercial value of Contrave/Mysimba; competition in the global obesity market, particularly from existing therapies; the company's failure to successfully acquire, develop and market additional product candidates or approved products; the company's ability to obtain and maintain global intellectual property protection for Contrave and Mysimba; the potential for an appeals  court to determine in our patent litigation matter with Actavis that one or more of the company's patents is not valid or that Actavis' proposed generic product is not infringing each of the patents at issue; other legal or regulatory proceedings against Orexigen, as well as potential reputational harm, as a result of misleading public claims about Orexigen; the company's ability to maintain sufficient capital to fund its operations for the foreseeable future; the company's ability to satisfy covenants in the indentures for its outstanding indebtedness, including one requirement that the company generate consolidated net product sales of least $100 million for fiscal year 2017; the company's ability to satisfy the applicable listing standards of the NASDAQ Global Market; and other risks described in Orexigen's filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks will be included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q which we intend to file with the Securities and Exchange Commission on or about November 13, 2017 and its other reports, which are available from the SEC's website ( and on Orexigen's website ( under the heading "Investors."  All forward‐looking statements are qualified in their entirety by this cautionary statement.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Orexigen Investor Contact:
Jason Keyes
Chief Financial Officer

Orexigen Media Contact:
Erika Hackmann

Orexigen Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands, except share and par value amounts)

September 30, 2017

December 31, 2016


(See Note below)


Current assets:

Cash and cash equivalents

$                   45,577

$                  92,494

Accounts receivable, net



Investment securities, available-for-sale



Restricted cash and investments





Prepaid expenses and other current assets



Total current assets



Property and equipment, net



Intangible assets



Other long-term assets



Restricted cash



Total assets

$                 183,747

$                304,589

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$                   10,933

$                  15,210

Accrued expenses



Contingent consideration


Deferred revenue, current portion



Total current liabilities



Long-term contingent consideration



Long-term convertible debt



Long-term convertible debt, at fair value



Deferred revenue, less current portion



Commitments and contingencies

Series Z preferred stock, $0.001 par value, 219,994 shares issued and outstanding at September 30, 2017 and December 31, 2016



Stockholders' equity:

Preferred stock, $0.001 par value, 10,000,000 shares authorized at  September 30, 2017 and December 31, 2016; 219,994 shares issued and outstanding at  September 30, 2017 and December 31, 2016, respectively

Common stock, $0.001 par value, 300,000,000 shares authorized at  September 30, 2017 and December 31, 2016; 15,601,157 and 14,616,751 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively



Additional paid-in capital



Accumulated other comprehensive income (loss)



Accumulated deficit



Total stockholders' equity (deficit)



Total liabilities and stockholders' equity 

$                 183,747

$                304,589

Note: The Balance Sheet at December 31, 2016 has been derived from the audited financial statements at that date.


Orexigen Therapeutics, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)


Three Months Ended September 30,

Nine Months Ended September 30,






Net product sales

$    18,768

$     5,241

$      61,041

$     8,176

Collaborative agreement








Total revenues





Cost of product sales





Operating expenses:

Research and development





Selling, general and administrative





Pre-existing settlement gain



Amortization expense of intangible assets





Change in fair value of contingent consideration





Total operating expenses





Income (loss) from operations





Other income (expense):

Interest income





Interest expense





Change in fair value of financial instruments





Gain on extinguishment of debt


Foreign currency gain (loss), net





Total other income (expense)





Net income (loss) - basic

$  (20,829)

$   47,663

$  (120,434)

$          85

Net income (loss) - diluted

$  (20,829)

$   40,963

$  (120,434)

$          85

Basic net income (loss) per share

$      (1.35)

$       3.27

$        (7.94)

$       0.01

Diluted net income (loss) per share

$      (1.35)

$       1.12

$        (7.94)

$       0.01

Basic shares used in computing net income (loss) per share





Diluted shares used in computing net income (loss) per share






View original content:

SOURCE Orexigen Therapeutics, Inc.